AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trial, New Data on XLRP Higher Dose Group and Financial Results for the Fourth Quarter and Year Ended June 30, 2020
– Planned Phase 2/3 trial expected to include approximately 60 patients and a responder analysis based on at least 7 […]